JP2024519031A5 - - Google Patents
Info
- Publication number
- JP2024519031A5 JP2024519031A5 JP2023571272A JP2023571272A JP2024519031A5 JP 2024519031 A5 JP2024519031 A5 JP 2024519031A5 JP 2023571272 A JP2023571272 A JP 2023571272A JP 2023571272 A JP2023571272 A JP 2023571272A JP 2024519031 A5 JP2024519031 A5 JP 2024519031A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- composition according
- group
- target
- moi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189503P | 2021-05-17 | 2021-05-17 | |
| US63/189,503 | 2021-05-17 | ||
| PCT/US2022/029533 WO2022245757A1 (en) | 2021-05-17 | 2022-05-17 | Compositions including conjugated therapy enhancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519031A JP2024519031A (ja) | 2024-05-08 |
| JP2024519031A5 true JP2024519031A5 (enExample) | 2025-05-23 |
Family
ID=84140038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571272A Pending JP2024519031A (ja) | 2021-05-17 | 2022-05-17 | コンジュゲート療法エンハンサーを含む組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240238436A1 (enExample) |
| EP (1) | EP4351658A4 (enExample) |
| JP (1) | JP2024519031A (enExample) |
| KR (1) | KR20240012376A (enExample) |
| CN (1) | CN117295527A (enExample) |
| AU (1) | AU2022277840A1 (enExample) |
| BR (1) | BR112023023506A2 (enExample) |
| CA (1) | CA3219475A1 (enExample) |
| IL (1) | IL307746A (enExample) |
| MX (1) | MX2023013274A (enExample) |
| PH (1) | PH12023553152A1 (enExample) |
| WO (1) | WO2022245757A1 (enExample) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3069986A1 (en) * | 2017-07-26 | 2019-01-31 | Kleo Pharmaceuticals, Inc. | Universal abt compounds and uses thereof |
| EP3773727A4 (en) * | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
| US10953107B2 (en) * | 2018-06-15 | 2021-03-23 | Trustees Of Boston University | Polypeptide compositions and methods for site-specific targeting of therapeutic agents |
| JP2023501720A (ja) * | 2019-11-18 | 2023-01-18 | クレオ ファーマシューティカルズ， インコーポレイテッド | 指向性コンジュゲーション技術 |
| WO2022192478A1 (en) * | 2021-03-10 | 2022-09-15 | Biohaven Therapeutics Ltd. | Bifunctional degraders of galactose-deficient immunoglobulins |
| CA3219517A1 (en) * | 2021-05-17 | 2022-11-24 | Wieslaw Kazmierski | Agents for directed conjugation techniques and conjugated products |
| US20250108124A1 (en) * | 2021-05-19 | 2025-04-03 | Biohaven Therapeutics Ltd. | Antibody drug conjugates using mates technology for delivering cytotoxic agents |
| WO2023043861A2 (en) * | 2021-09-16 | 2023-03-23 | Biohaven Therapeutics Ltd. | Conjugated antibodies for treating diseases |
-
2022
- 2022-05-17 MX MX2023013274A patent/MX2023013274A/es unknown
- 2022-05-17 AU AU2022277840A patent/AU2022277840A1/en active Pending
- 2022-05-17 US US18/555,855 patent/US20240238436A1/en active Pending
- 2022-05-17 BR BR112023023506A patent/BR112023023506A2/pt unknown
- 2022-05-17 EP EP22805273.4A patent/EP4351658A4/en active Pending
- 2022-05-17 PH PH1/2023/553152A patent/PH12023553152A1/en unknown
- 2022-05-17 CA CA3219475A patent/CA3219475A1/en active Pending
- 2022-05-17 WO PCT/US2022/029533 patent/WO2022245757A1/en not_active Ceased
- 2022-05-17 KR KR1020237039153A patent/KR20240012376A/ko active Pending
- 2022-05-17 IL IL307746A patent/IL307746A/en unknown
- 2022-05-17 CN CN202280034211.XA patent/CN117295527A/zh active Pending
- 2022-05-17 JP JP2023571272A patent/JP2024519031A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501720A5 (enExample) | ||
| CN101541347B (zh) | 药物载体、其合成及其使用方法 | |
| JP7073266B2 (ja) | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス | |
| DE60206272T2 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
| JP2005507376A (ja) | ペプチドベースの化合物 | |
| JP2010174013A (ja) | 組織ダメージの治療と予防 | |
| BR122019000248B1 (pt) | reagente de ligador de pró-fármaco de cascata polimérico | |
| DK2806896T3 (en) | Chitosan covalently bound to small molecule integrin antagonist for targeted delivery | |
| JP2005531559A5 (enExample) | ||
| JP2023535026A5 (enExample) | ||
| JPWO2013081091A1 (ja) | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 | |
| JPWO1994003424A1 (ja) | 脳内滞留性化合物およびその用途 | |
| JP2018531287A5 (enExample) | ||
| JP2024509282A5 (enExample) | ||
| US6365592B1 (en) | Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP-1B) | |
| JP2024521092A5 (enExample) | ||
| JP2024519031A5 (enExample) | ||
| JP7249591B2 (ja) | 分解性ポリエチレングリコール結合体 | |
| EP3872084A1 (en) | Epi-x4 based peptides and derivatives thereof | |
| WO2015076359A1 (ja) | プロテアソーム阻害性化合物 | |
| JP2002503674A5 (enExample) | ||
| DE69816241T2 (de) | Aktivierte peptide und konjugate | |
| DE69304538T2 (de) | Aminosäure-derivate und deren verwendung | |
| Inman et al. | Synthesis of N. alpha.-(tert-butoxycarbonyl)-N. epsilon.-[N-(bromoacetyl)-. beta.-alanyl]-L-lysine: Its use in peptide synthesis for placing a bromoacetyl cross-linking function at any desired sequence position | |
| JP2003503465A (ja) | 分子間で会合した化合物とこれらの化合物を含む凝集体 |